Nuwellis Reports 26% Sales Growth to $2.4M, Completes Rendiatech Acquisition and Secures Pediatric Patent
NUWE•Nuwellis’ first-quarter net sales rose 26% year-over-year to $2.4 million with gross margin expanding to 70.1% on improved pricing and contract manufacturing. The company completed the Rendiatech acquisition, appointed a new CFO, expanded commercial coverage in South Texas and secured patents for pediatric therapy and dual-lumen catheter designs.
1. First Quarter Financial Results
Nuwellis reported revenue of $2.4 million for the quarter ended March 31, 2026, a 26% increase over the prior-year period. Gross margin improved to 70.1% driven by better pricing, product mix and a shift to contract manufacturing, while operating expenses rose to $6.0 million and net loss was $4.3 million. The company held $2.2 million in cash and equivalents with no debt on March 31.
2. Acquisition and Technology Portfolio
The company completed its acquisition of Rendiatech, adding automated kidney-function monitoring capabilities to its development pipeline. It also received issuance of a patent for pediatric extracorporeal therapy safety and a notice of allowance for its dual-lumen midline catheter technology in ultrafiltration treatments.
3. Leadership and Board Updates
Carisa Schultz was appointed Chief Financial Officer and Dr. Stuart L. Goldstein joined as Director of Clinical Strategy. Martin J. Emerson was added and David A. McDonald was reappointed to the Board of Directors, strengthening governance and clinical oversight.
4. Commercial Expansion
Nuwellis expanded its commercial footprint with a new South Texas territory and reinstated experienced Aquadex sales leaders. The company noted continued pediatric therapy momentum alongside growth in adult heart failure and critical care segments, underpinning its cardiorenal strategy.
